3SBio Inc. — Capital/Financing Update 2020

Mar 9, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or on reliance upon the whole or any part of the contents of this announcement.

==> picture [110 x 133] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT

SUNSHINE GUOJIAN’S PARTNER NUMAB THERAPEUTICS CLOSES SERIES B FINANCING

Reference is made to the announcement of the Company dated 12 December 2019 (“ Announcement ”). Unless the context otherwise requires, capitalized terms used herein shall have the same meaning as those defined in the Announcement.

The Company wishes to inform the shareholders of the Company of the attached press release in respect of the closing of the Series B financing of Numab at a total volume of CHF22 million (approximately USD22.6 million), with investors including Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member, Dr. Daniel Vasella.

This is a voluntary announcement made by the Company. The Company cannot guarantee that Numab will be able to broaden its proprietary pipeline and accelerate the clinical development for a number of programs and initiate a clinical trial for the lead oncology program ND021 during the course of 2020. Shareholders of the Company and potential investors are advised to exercise due care when dealing in the shares of the Company.

By order of the Board 3SBio Inc. Dr. LOU Jing Chairman

Shenyang, the PRC 9 March 2020

As at the date of this announcement, the directors of the Company are Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Dr. WONG Lap Yan as independent non-executive directors.

1

==> picture [85 x 34] intentionally omitted <==

==> picture [174 x 36] intentionally omitted <==

Press Release

3S Sunshine Guojian Partner Numab Therapeutics Closes Series B Financing

SHANGHAI, China and WAEDENSWIL, Switzerland — March 9, 2020 — Numab Therapeutics announced today the closing of its Series B financing round at a total volume of CHF 22M (approximately USD22.6M). New investors in this round included 3SBio Group’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella. Numab’s existing shareholders also contributed to the financing round. Sunshine Guojian invested CHF15M in this series B financing in December 2019. Dr. Zhenping Zhu, MD, PhD, President of Research and Development and Chief Scientific Officer of 3SBio, has joined the Numab’s board of directors. With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the clinical development for a number of programs. Numab also plans to initiate a clinical trial for its lead oncology program ND021 during the course of 2020.

Mitsubishi UFJ Capital is one of Asia’s leading venture capital firm focusing on life science, information and communications technology and high technology investments. Numab and Eisai entered into a global research and option agreement to discover and develop a portfolio of multispecific antibody immunotherapies for cancer in October 2019. In December 2019, Numab added a regional alliance with Sunshine Guojian to its growing roster of pharmaceutical partnerships.

“We are very pleased to have attracted a renowned institutional investor in Mitsubishi UFJ Capital to the Numab story and likewise appreciate the additional display of confidence in our platform and pipeline strategy by our partners as well as by our existing Series A investors and our board member Dr. Daniel Vasella,” commented Dr. David Urech, Chief Executive Officer of Numab Therapeutics.

“3SBio is committed to developing innovative cancer cures. The investment and collaboration with Numab are consistent with our strategies and we are looking forward to collaborating with the Numab team to explore cutting edge immunotherapies in oncology.” said Dr. Jing Lou, Chairman and Chief Executive Officer of 3SBio.

Compared with conventional immunotherapies in oncology, multi-specific antibodies have the potential to unlock entirely novel modes-of-action aiming at superior benefit-to-risk profiles. Numab’s proprietary MATCH™ technology platform represents one of the most versatile and flexible sources for multi-specific antibodies. MATCH™ molecules can incorporate up to six binding specificities in true plug-and-play fashion. The individual antibody Fv building blocks are designed for maximum stability and developability.

2

==> picture [85 x 34] intentionally omitted <==

==> picture [174 x 36] intentionally omitted <==

About Numab Therapeutics

Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. Numab is writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With the proprietary MATCH™ technology platform, Numab is fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Numab’s lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. Numab believes meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit www.numab.com.

About Sunshine Guojian

Sunshine Guojian was established in 2002 and is one of the first batch of innovative biopharmaceutical companies focusing on antibody drugs in China. It is the only domestic pharmaceutical company that has two launched therapeutic antibody drugs, and had emerged as a leader in antibody drug with its capabilities of independent R&D, industrialization and commercialization in China. Sunshine Guojian orients its R&D efforts primarily towards innovative therapeutic antibody drugs, and provides quality, safe and effective clinical solutions to the therapeutic areas of major diseases such as auto-immune diseases and tumors. Currently, Sunshine Guojian has 15 anti-body drug candidates (including 7 drug candidates in clinical and new drug registration stage and 8 drug candidates in pre-clinical stage) which are under different development stages, targeting tumor, auto-immune diseases and ophthalmological diseases. Most of those drug candidates are Category I biological products for therapeutic use or monoclonal antibodies, 2 of which are in application for launching, and 5 are in clinical stage. Sunshine Guojian may submit applications to both the National Medical Products Administration and the US Food and Drug Administration for some of those drug candidates, or some may be admitted for priority evaluation. Please visit www.3s-guojian.com for additional information.

About 3SBio

3SBio is a fully-integrated biotechnology company in China with market-leading biopharmaceutical franchises in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is focusing on building an innovative product pipeline, currently with over 30 product candidates under development. 3SBio’s manufacturing capabilities include recombinant proteins, monoclonal antibodies and chemically-synthesized molecules. 3SBio has research and production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Como, Italy. Please visit www.3sbio.com for additional information.

3